JAMA: Anticoagulation can be shortened to 6 weeks in patients under 21 years of age with induced venous thromboembolism

Anticoagulant therapy for venous thrombosis began in the 1960s, and long-term clinical evidence has shown that anticoagulant therapy is beneficial in reducing the risk of recurrence of venous thromboembolism
.

Recurrent venous thromboembolism including deep vein thrombosis (DVT) and pulmonary embolism - Recurrent deep vein thrombosis increases the risk of chronic venous insufficiency (post-thrombotic syndrome), and patients with pulmonary embolism have an extremely high risk of death

We investigated the effect of reducing the duration of anticoagulation therapy to 6 weeks in patients with acutely induced venous thromboembolism younger than 21 years of

The 1-year cumulative symptomatic recurrent venous thromboembolism rates were 0.
66% and 0.
70% in the 6-week anticoagulation group and 0.

CONCLUSIONS: In patients with induced venous thromboembolism under the age of 21, 6-week anticoagulation therapy was comparable to the traditional 3-month regimen in reducing the risk of recurrent thrombosis and bleeding safety, meeting non-inferiority criteria
.

In patients under 21 years of age with induced venous thromboembolism, 6-week anticoagulation was comparable to the traditional 3-month regimen in reducing the risk of recurrent thrombosis and bleeding safety, meeting noninferiority criteria
.
In patients under 21 years of age with induced venous thromboembolism, 6-week anticoagulation was comparable to the traditional 3-month regimen in reducing the risk of recurrent thrombosis and bleeding safety, meeting noninferiority criteria
.

Original Source:
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism The Kids-DOTT Randomized Clinical Trial.
JAMA WRITING HERE